Muscarinic M1 agonist - Nxera Pharma
Latest Information Update: 02 Apr 2024
At a glance
- Originator Sosei Heptares
- Developer Nxera Pharma
- Class Small molecules
- Mechanism of Action Muscarinic M1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Neurological disorders